ReviewRespiratory physiology & neurobiology2021
Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.
Review in Respiratory physiology & neurobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Lucinactant, a Synthetic Surfactant for the Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19: Phase 1/2A Trial.JMIR formative research · 2026Trial
- Review
- Reassessing adult surfactant replacement therapy with mechanics-informed reinforcement learning.PLoS computational biology · 2026Article
- Epigallocatechin-3-gallate ameliorates lipopolysaccharide-induced inflammation via the 67LR/JAK2/STAT3 signaling pathway.Scientific reports · 2025Article
- Lung Surfactant Deficiency in Severe Respiratory Failure: A Potential Biomarker for Clinical Assessment.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Evolution of interfacial mechanics of lung surfactant mimics progression of acute respiratory distress syndrome.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review.Bioscience reports · 2023Review
- Lung Surfactant Protein B Peptide Mimics Interact with the Human ACE2 Receptor.International journal of molecular sciences · 2023Article
- The Epithelial Sodium Channel-An Underestimated Drug Target.International journal of molecular sciences · 2023Review
- Metabolomic characterization benefits the identification of acute lung injury in patients with type A acute aortic dissection.Frontiers in molecular biosciences · 2023Article
- Article
- Confocal Laser Endomicroscopy in a Critically Ill COVID-19 Patient.Tuberculosis and respiratory diseases · 2022Article
- Severe COVID-19 ARDS Treated by Bronchoalveolar Lavage with Diluted Exogenous Pulmonary Surfactant as Salvage Therapy: In Pursuit of the Holy Grail?Journal of clinical medicine · 2022Article
- Estimating the incidence of spontaneous breathing effort of mechanically ventilated patients using a non-linear auto regressive (NARX) model.Computer methods and programs in biomedicine · 2022Article
- Article
- Pulmonary surfactant as a versatile biomaterial to fight COVID-19.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Alveolar type II cells and pulmonary surfactant in COVID-19 era.Physiological research · 2021Review
- The International Week of Surfactant Research: Increasing knowledge about surfactant and unexploited opportunities.Biomedical journal · 2021Article
- Ultra- and micro-structural changes of respiratory tracts in SARS-CoV-2 infected Syrian hamsters.Veterinary research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells, COVID-19 interferes with the production and secretion of the pulmonary surfactant and therefore causes an increase in surface tension, which in turn can lead to alveolar collapse. The use of the pulmonary surfactant seems to be promising as an additional therapy for the treatment of ARDS. COVID-19 causes lung damage and ARDS, so beneficial effects of surfactant therapy in COVID-19-associated ARDS patients are conceivable, especially when applied early in the treatment strategy against pulmonary failure. Because of the robust anti-inflammatory and lung protective efficacy and the current urgent need for lung-supportive therapy, the exogenous pulmonary surfactant could be a valid supportive treatment of COVID-19 pneumonia patients in intensive care units in addition to the current standard of ARDS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.